Evaluating Carbon Footprint of Proton Therapy Based on Power Consumption and Possible Mitigation Strategies
CONCLUSION: Carbon footprint varied by disease treated and was on average 23 kg of CO2e per patient, and 253.7 tons of CO2e for the proton program. There are a number of reduction, mitigation and offset strategies possible for radiation oncologists that should be explored such as waste minimization, less treatment commuting, efficient energy use, and renewable electricity power use.PMID:37244624 | DOI:10.1016/j.ijrobp.2023.05.022 (Source: Health Physics)
Source: Health Physics - May 27, 2023 Category: Physics Authors: Tomas Dvorak Sanford Meeks Lucas Dvorak Justin Rineer Patrick Kelly Naren Ramakrishna Thomas Henig Murat Kucukvar Nuri C Onat Omer Tatari Amish Shah Jessica Salazar Omar Zeidan Source Type: research
Independent Association of Metabolic Tumor Response on FDG-PET with Pulmonary Toxicity Following Risk-Adaptive Chemoradiation for Unresectable Non-Small Cell Lung Cancer: Inherent Radiosensitivity or Immune Response?
CONCLUSION: Tumor metabolic response as measured by mean SUV is associated with increased pneumonitis risk in a clinical trial cohort of NSCLC patients independent of treatment factors. This may be partially attributed to patient-specific differences in immunogenicity.PMID:37244360 | DOI:10.1016/j.radonc.2023.109720 (Source: Radiotherapy and Oncology : journal of the European Society for Therapeutic Radiology and Oncology)
Source: Radiotherapy and Oncology : journal of the European Society for Therapeutic Radiology and Oncology - May 27, 2023 Category: Radiology Authors: Evan D H Gates Daniel S Hippe Hubert J Vesselle Jing Zeng Stephen R Bowen Source Type: research
Independent Association of Metabolic Tumor Response on FDG-PET with Pulmonary Toxicity Following Risk-Adaptive Chemoradiation for Unresectable Non-Small Cell Lung Cancer: Inherent Radiosensitivity or Immune Response?
CONCLUSION: Tumor metabolic response as measured by mean SUV is associated with increased pneumonitis risk in a clinical trial cohort of NSCLC patients independent of treatment factors. This may be partially attributed to patient-specific differences in immunogenicity.PMID:37244360 | DOI:10.1016/j.radonc.2023.109720 (Source: Radiotherapy and Oncology : journal of the European Society for Therapeutic Radiology and Oncology)
Source: Radiotherapy and Oncology : journal of the European Society for Therapeutic Radiology and Oncology - May 27, 2023 Category: Radiology Authors: Evan D H Gates Daniel S Hippe Hubert J Vesselle Jing Zeng Stephen R Bowen Source Type: research
Postmastectomy Intensity Modulated Proton Therapy: 5-Year Oncologic and Patient-Reported Outcomes
: To report oncologic, physician-assessed, and patient-reported outcomes (PROs) of a group of women homogeneously treated with modern, skin-sparing multi-field optimized pencil-beam scanning proton (intensity modulated proton therapy [IMPT]) postmastectomy radiotherapy (PMRT). (Source: International Journal of Radiation Oncology * Biology * Physics)
Source: International Journal of Radiation Oncology * Biology * Physics - May 25, 2023 Category: Radiology Authors: Robert W. Gao, Trey C. Mullikin, Khaled A. Aziz, Arslan Afzal, Na L. Smith, David M. Routman, Kimberly R. Gergelis, William S. Harmsen, Nicholas B. Remmes, Hok Seum Wan Chan Tseung, Satomi S. Shiraishi, Judy C. Boughey, Kathryn J. Ruddy, Christin A. Harle Source Type: research
Evaluating Carbon Footprint of Proton Therapy Based on Power Consumption and Possible Mitigation Strategies
This study quantifies the energy utilization of proton therapy, corresponding carbon footprint, and discusses possible offsetting strategies towards carbon-neutral healthcare operations. (Source: International Journal of Radiation Oncology * Biology * Physics)
Source: International Journal of Radiation Oncology * Biology * Physics - May 25, 2023 Category: Radiology Authors: Tomas Dvorak, Sanford Meeks, Lucas Dvorak, Justin Rineer, Patrick Kelly, Naren Ramakrishna, Thomas Henig, Murat Kucukvar, Nuri C. Onat, Omer Tatari, Amish Shah, Jessica Salazar, Omar Zeidan Tags: Clinical Investigation Source Type: research
Range verification of a clinical proton beam in an abdominal phantom by co-registration of ionoacoustics and ultrasound
Phys Med Biol. 2023 May 23. doi: 10.1088/1361-6560/acd834. Online ahead of print.ABSTRACTThe range uncertainty in proton radiotherapy is a limiting factor to achieve optimum dose conformity to the tumour volume. Ionoacoustics is a promising approach for in-situ range verification, which would allow to reduce the size of the irradiated volume relative to the tumour volume. The energy deposition of a pulsed proton beam leads to an acoustic pressure wave (ionoacoustics), the detection of which allows conclusion about the distance between the Bragg peak and the acoustic detector. This information can be transferred into a co-r...
Source: Physics in Medicine and Biology - May 23, 2023 Category: Physics Authors: Jannis Schauer Hans-Peter Wieser Julie Lascaud Yuanhui Huang Marie Vidal Joel Herault Vasilis Ntziachristos G ünther Dollinger Katia Parodi Source Type: research
Range verification of a clinical proton beam in an abdominal phantom by co-registration of ionoacoustics and ultrasound
Phys Med Biol. 2023 May 23. doi: 10.1088/1361-6560/acd834. Online ahead of print.ABSTRACTThe range uncertainty in proton radiotherapy is a limiting factor to achieve optimum dose conformity to the tumour volume. Ionoacoustics is a promising approach for in-situ range verification, which would allow to reduce the size of the irradiated volume relative to the tumour volume. The energy deposition of a pulsed proton beam leads to an acoustic pressure wave (ionoacoustics), the detection of which allows conclusion about the distance between the Bragg peak and the acoustic detector. This information can be transferred into a co-r...
Source: Physics in Medicine and Biology - May 23, 2023 Category: Physics Authors: Jannis Schauer Hans-Peter Wieser Julie Lascaud Yuanhui Huang Marie Vidal Joel Herault Vasilis Ntziachristos G ünther Dollinger Katia Parodi Source Type: research
Range verification of a clinical proton beam in an abdominal phantom by co-registration of ionoacoustics and ultrasound
Phys Med Biol. 2023 May 23. doi: 10.1088/1361-6560/acd834. Online ahead of print.ABSTRACTThe range uncertainty in proton radiotherapy is a limiting factor to achieve optimum dose conformity to the tumour volume. Ionoacoustics is a promising approach for in-situ range verification, which would allow to reduce the size of the irradiated volume relative to the tumour volume. The energy deposition of a pulsed proton beam leads to an acoustic pressure wave (ionoacoustics), the detection of which allows conclusion about the distance between the Bragg peak and the acoustic detector. This information can be transferred into a co-r...
Source: Physics in Medicine and Biology - May 23, 2023 Category: Physics Authors: Jannis Schauer Hans-Peter Wieser Julie Lascaud Yuanhui Huang Marie Vidal Joel Herault Vasilis Ntziachristos G ünther Dollinger Katia Parodi Source Type: research
Cancers, Vol. 15, Pages 2882: Clinical Characterization of a Table Mounted Range Shifter Board for Synchrotron-Based Intensity Modulated Proton Therapy for Pediatric Craniospinal Irradiation
Conclusions: A custom RSB for pediatric proton CSI was designed, manufactured, modeled in our TPS, and found to significantly reduce lateral proton beam penumbra compared to a standard MRS while maintaining CBCT and kV image-quality and is in routine use at our center. (Source: Cancers)
Source: Cancers - May 23, 2023 Category: Cancer & Oncology Authors: William T. Hrinivich Heng Li Anh Tran Sahaja Acharya Matthew M. Ladra Khadija Sheikh Tags: Article Source Type: research
Critical Appraisal of Proton Therapy for Patients with Central Nervous System (CNS) Malignancies
Opinion statementAs more hospital-based proton treatment centres become operational, the indications for proton beam therapy (PBT) are being evaluated. Recent advances in PBT technology are expanding the indications for the use of protons in the treatment of central nervous system (CNS) tumours. Prospective trials that assess the late toxicity of different radiation therapy (RT) techniques are needed to confirm any expected reduction in long-term side effects with PBT. The ASTRO Model Policy on proton beam therapy currently supports the reasonable use of protons in the treatment of specific CNS tumour types. Specifically, ...
Source: Current Treatment Options in Oncology - May 22, 2023 Category: Cancer & Oncology Source Type: research
Transitioning from conventional photon therapy to proton therapy for primary brain tumors
CONCLUSION: Contrary to previous studies, there was no difference in risk of PsP for XRT and PT. PT was associated with lower rates of fatigue <3 months after RT. The superior survival outcomes for PT indicates that the patients with the best prognosis were referred to PT.PMID:37203198 | DOI:10.1080/0284186X.2023.2200150 (Source: Acta Oncologica)
Source: Acta Oncologica - May 19, 2023 Category: Cancer & Oncology Authors: Hanna Ek Ingrid Fagerstr öm Kristensen Lars Stenberg Sara Kinhult Hunor Benedek Simon Ek Svend Aage Engelholm Silke Engelholm Per Munck Af Rosensch öld Source Type: research
Transitioning from conventional photon therapy to proton therapy for primary brain tumors
CONCLUSION: Contrary to previous studies, there was no difference in risk of PsP for XRT and PT. PT was associated with lower rates of fatigue <3 months after RT. The superior survival outcomes for PT indicates that the patients with the best prognosis were referred to PT.PMID:37203198 | DOI:10.1080/0284186X.2023.2200150 (Source: Acta Oncologica)
Source: Acta Oncologica - May 19, 2023 Category: Cancer & Oncology Authors: Hanna Ek Ingrid Fagerstr öm Kristensen Lars Stenberg Sara Kinhult Hunor Benedek Simon Ek Svend Aage Engelholm Silke Engelholm Per Munck Af Rosensch öld Source Type: research
Transitioning from conventional photon therapy to proton therapy for primary brain tumors
CONCLUSION: Contrary to previous studies, there was no difference in risk of PsP for XRT and PT. PT was associated with lower rates of fatigue <3 months after RT. The superior survival outcomes for PT indicates that the patients with the best prognosis were referred to PT.PMID:37203198 | DOI:10.1080/0284186X.2023.2200150 (Source: Acta Oncologica)
Source: Acta Oncologica - May 19, 2023 Category: Cancer & Oncology Authors: Hanna Ek Ingrid Fagerstr öm Kristensen Lars Stenberg Sara Kinhult Hunor Benedek Simon Ek Svend Aage Engelholm Silke Engelholm Per Munck Af Rosensch öld Source Type: research
Phase II Trial of Combined Durvalumab Plus Tremelimumab with Proton Therapy for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
CONCLUSION: The combination of durvalumab/tremelimuab with proton therapy was tolerated well and had encouraging anti-tumor efficacy in non-irradiated tumor lesions of heavily-treated HNSCC patients.PMID:37202212 | DOI:10.4143/crt.2023.502 (Source: Cell Research)
Source: Cell Research - May 18, 2023 Category: Cytology Authors: Hana Kim Sehhoon Park Hyun Ae Jung Se-Hoon Lee Keunchil Park Yong Chan Ahn Dongryul Oh Myung-Ju Ahn Source Type: research
Robustness of multifield pseudo-arc proton therapy for sinonasal cancer
Acta Oncol. 2023 May 17:1-5. doi: 10.1080/0284186X.2023.2214320. Online ahead of print.NO ABSTRACTPMID:37194287 | DOI:10.1080/0284186X.2023.2214320 (Source: Acta Oncologica)
Source: Acta Oncologica - May 17, 2023 Category: Cancer & Oncology Authors: Raul Argota-Perez Ulrik V Elstr øm Kenneth Jensen Stine S Korreman Source Type: research
